Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Personal Genome Diagnostics And Cleveland Diagnostics Will Use New Funding To Expand Cancer Portfolios

Executive Summary

Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.

You may also be interested in...



Minute Insight: Quidel And Labcorp Finish Big Year For IVD Deals With Major Acquisitions

Quidel will pay $6bn for Ortho Clinical Diagnostics. Labcorp will acquire Personal Genome Diagnostics for $575m.

Wi-Fi Failures, Custom Tech And Other Challenges Of Bringing Specialty Care Into Patients’ Homes

The CEOs Reimagine Care, Cortica and Inbound Health, part of the rising trend to bring specialty and acute care programs into the home, joined a panel at the DHIS West conference to discuss their views on the future of virtual and at-home delivery of complex care and shared some of their own challenges they encountered. 

Minute Insight: Thermo Fisher Scientific Wins FDA Clearance For Preeclampsia Blood Test

The FDA cleared Thermo Fisher’s in vitro diagnostic for preeclampsia, the leading cause of pregnancy morbidity and mortality, based on results from the PRAECIS study.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel